A hearty solution for acute myeloid leukemia

Hung, Yi Ju; Liu, H. Eugene

doi:10.1038/aps.2011.197

Cited by 10 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some clinical trials are currently focused on the cytotoxicity and possible uses of cardiac glycosides in cancer treatment. A phase-I trial is testing ouabain for the treatment of acute myeloid leukemia [198]; PBI-05204 based on oleandrin, is in a phase-I trial testing its effect on solid tumours [199], and the combination of erlotinib with digoxin is being used in a phase-II trial with patients suffering from non-small cell lung cancer [200]. It seems that some cardiac glycoside-based compounds will undergo the clinical testing alone or in combination with approved anticancer agents.…”

Section: Cardiac Glycosides In Cancer Treatmentmentioning

confidence: 99%

From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment

Babula¹,

Masařík²,

Adam³

et al. 2013

ACAMC

View full text Add to dashboard Cite

The cardiac glycosides are a group of compounds isolated from plants and some animals. They have been used in therapy for heart failure for many years. The cytotoxic effect of many cardiac glycosides has been demonstrated, but the mechanism of action is very complicated and complex, and Na+/K+-ATPase surely plays a crucial role in it. On the other hand, Na+/K+-ATPase is regulated by many endogenous factors, such as hormones or FXYD proteins, whose role in regulating the cell cycle has been studied intensively. This review focuses on the role of Na+/K+-ATPase in regulating the cell growth, the cell cycle and the cell proliferation and on the involvement of cardiac glycosides in regulating Na+/K+-ATPase. The cytotoxic effect of cardiac glycosides is discussed with respect to the apoptotic mechanisms possibly induced by these compounds. Novel strategies in cancer therapy based on cardiac glycosides are discussed as are possibilities for counteracting multidrug resistance by using cardiac glycosides. The aim of this review is to present cardiac glycosides not only as pharmaceuticals used in the management of heart failure, but also as potent cytotoxic agents with potential uses in cancer treatment.

show abstract

Section: Cardiac Glycosides In Cancer Treatmentmentioning

confidence: 99%

From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment

Babula¹,

Masařík²,

Adam³

et al. 2013

ACAMC

View full text Add to dashboard Cite

show abstract

“…Bearing in mind the examples of effects observed in cancer cells exposed to cardiac glycosides, exploring their anticancer effect is an interesting approach, since they have been on the market for decades. In this sense, due to the high cost and long period required for research & development (R&D) of new drugs as anticancer agents, the discovery of such potential drugs that are already known and used clinically can be considered a relevant short cut, which can contribute much in this area of the pharmaceutical industry (Hung and Liu 2012).…”

Section: Introductionmentioning

confidence: 99%

Digoxin reduces the mutagenic effects of Mitomycin C in human and rodent cell lines

et al. 2017

View full text Add to dashboard Cite

Digoxin is a drug widely used to treat heart failure and studies have demonstrated its potential as anticancer agent. In addition, digoxin presents the potential to interact with a series of other compounds used in medicine. The aim of the present study was to evaluate in vitro the cytotoxicity, genotoxicity and mutagenicity of digoxin and its potential to interact with the mutagen Mitomycin C (MMC). The cytotoxicity of digoxin was assessed by employing the MTT method and the comet assay was performed to assess the genotoxicity of this medicine in CHO-K1 and HeLa cell lines. Besides, the cytokinesis-block micronucleus assay was performed to assess the mutagenicity and the antimutagenicity of this drug. The Ames assay was also performed with TA98 and TA100 strains of S. typhimurium. Results showed that digoxin was cytotoxic, genotoxic and mutagenic for HeLa and CHO-K1 cell lines at concentrations many times higher than those observed in human therapeutic conditions. Nevertheless, an antimutagenic effect against the mutagen MMC was observed on both cell lines in concentrations near those used therapeutically in humans. This chemoprotective effect observed is an interesting finding that should be better explored regarding its impact in anticancer chemotherapy.

show abstract